aleniglipron vs zovaglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Obesitysmall molecule
Partial signal

NCT06703021 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: September 2028 · NCT07654361 (registry estimate)

Reported efficacy

Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Baseline and week 44); Adverse events of special interest (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature (Baseline and week 44): Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) (not_applicable)

Result source: NCT06703021

zovaglutide

Developed by Beijing QL Biopharmaceutical

Phase 3 in Obesitypeptide
Reliable signal

NCT07020884 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial (n=303) in adults with overweight or obesity found that ZT002 produced significantly greater weight loss than placebo at 24 weeks across all doses tested, up to 14.4% versus 2.4% with placebo (p<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT07443059 (registry estimate)

Reported efficacy

The percentage change from baseline in weight after 24 weeks of treatment. (baseline, 24 weeks): Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001. (met)

Result source: NCT07020884

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointaleniglipronzovaglutide
Body weight, % change—Trial running · NCT07654361-13.8% vs -2.4%a−11.4 vs placebo160mg monthly · wk 24NCT07020884
3 other results
  • -14.4% vs -2.4% 160mg biweekly · wk 24 · Phase 2 · primary NCT07020884
  • -10.6% vs -2.4% 80mg monthly · wk 24 · Phase 2 · primary NCT07020884
  • -12.5% vs -2.4% 80mg biweekly · wk 24 · Phase 2 · primary NCT07020884
Weight loss of 5% or more—Trial running · NCT07654361—Trial running · NCT07230119
Weight loss of 10% or more—Trial running · NCT07654361—Trial running · NCT07230119
Waist circumference, change (cm)—Trial running · NCT07654361—Trial running · NCT07230119

Body weight, % change

aleniglipron
—Trial running · NCT07654361
zovaglutide
-13.8% vs -2.4%a−11.4 vs placebo160mg monthly · wk 24NCT07020884
3 other results
  • -14.4% vs -2.4% 160mg biweekly · wk 24 · Phase 2 · primary NCT07020884
  • -10.6% vs -2.4% 80mg monthly · wk 24 · Phase 2 · primary NCT07020884
  • -12.5% vs -2.4% 80mg biweekly · wk 24 · Phase 2 · primary NCT07020884

Weight loss of 5% or more

aleniglipron
—Trial running · NCT07654361
zovaglutide
—Trial running · NCT07230119

Weight loss of 10% or more

aleniglipron
—Trial running · NCT07654361
zovaglutide
—Trial running · NCT07230119

Waist circumference, change (cm)

aleniglipron
—Trial running · NCT07654361
zovaglutide
—Trial running · NCT07230119
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) NCT06703021 · Phase 2 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

zovaglutide

Weight -13.8% vs -2.4% placebo @ 24wk160mg monthly
percent change · % of baseline
NCT07020884 · Phase 2 · sponsor-reported, not registry data
show 3 more results
-14.4% vs -2.4% placebo @ 24wk160mg biweekly
NCT07020884 · Phase 2 · sponsor-reported, not registry data
-10.6% vs -2.4% placebo @ 24wk80mg monthly
NCT07020884 · Phase 2 · sponsor-reported, not registry data
-12.5% vs -2.4% placebo @ 24wk80mg biweekly
NCT07020884 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · zovaglutide's landscape